Latest news with #ODD
Yahoo
16-05-2025
- Business
- Yahoo
Conneaut pursuing comprehensive zoning reform
CONNEAUT — The city is looking to conduct a comprehensive zoning reform this year, City Manager Nick Sanford said. He said the city identified the need for zoning reform in an update to its comprehensive plan in 2018. 'Our zoning text by and large dates back in 1982,' Sanford said. The city needs to update its zoning codes to reflect the fact it is not 1982 anymore, he said. 'Our zoning code's just old, frankly,' he said. City leadership is interested in reforms that work out for both residents and developers, Sanford said. Sanford is interested in having the zoning districts have more flexibility for development and applications for development, while working to preserve historic buildings in the city, he said. Sanford said the update has to focus on the fact Conneaut is geographically diverse, with a coastline and rural and urban areas. 'It's imperative that we are mindful of that,' he said. Sanford was thankful for the work of previous city administrations and councils for what they could do to pursue the issue, despite the COVID-19 pandemic, he said. Sanford is interested in having the zoning reforms done by the end of the year, he said. 'I think it's an achievable goal,' he said. The city is still in the early stages of the project, Sanford said. 'We're essentially testing waters to get started in this,' he said. Sanford said he wants to have community workshops to hear from residents. None are planned yet, he said. The city was interested in getting a grant from the Ohio Department of Development to fund the project. Council passed a resolution approving the grant application at an April 28 meeting. Sanford said ODD received around $2 million in requests, and had to close the window for funding applications early. 'This is something we're still going to pursue without funding,' he said. Sanford said MS Consultants, an engineering firm the city uses, has several employees versed in the nuances of zoning reform and law, who can help the city.
Yahoo
14-05-2025
- General
- Yahoo
Woman Says She's Naming Baby After Late Grandma, Even Though Her Sister Also Wants to Use the Name
A woman is fighting with her sister after naming her child after their late grandmother — a name the sister also wanted to use for a future child In a post shared to Reddit, the woman writes that she was closer with the grandmother than the sister was, even living with the woman in her childhood But the sister is now so upset she's brought their parents into the mixA woman says she's not sure what to do after her sister became "furious" that she named her daughter after their late grandmother — because the sister wanted to use the name, too. In a post shared on Reddit, the anonymous, 30-year-old woman writes that she and her sister are "not very close," and that the two lived apart during their childhood. "I lived with my grandma because my sister had ODD (oppositional defiant disorder) and a conduct disorder," the woman writes, adding, "I bonded deeply with grandma in the years I lived with her and I didn't want to go home when I did." She continues: "But my sister was stable enough by then for me to live with her and my parents again. Our relationship never got better from that point. We learned to be civil but there's no love lost between us." There were some tensions, the woman writes, when her grandmother died because she left her "a few special treasures" but left none to her sister. While the two had a falling out, they kept in touch sporadically and, when the poster found out she was pregnant, she told her family she had decided to name the child after her grandmother. "My sister told me I couldn't use grandma's name because she wanted to use it for a future daughter. She told me I didn't get to have the name," the woman writes. "Someone else said that nobody could claim a name and there was no reason we both couldn't use it." The woman then gave birth and did use the name, and her sister is now "furious." Their parents, meanwhile, are siding with the sister, "asking why I didn't just find a different name and let her use it." "They said after all she's been through and the stuff with inheritance I should be more understanding," she writes of her parents. "It annoyed me. My husband couldn't believe my parents would side with my sister on this." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Hundreds of people have weighed in on the post, with many saying the woman did "nothing wrong." "There is nothing you can do to prevent her from getting annoyed with you, and would find fault with anything you do. You did nothing wrong," writes one. Added another commenter: "Your daughter's name is a beautiful tribute to your beloved grandmother and your sister's behavior is just plain childish. Don't let her petty jealousy and entitlement ruin such a special moment for you and your family." Read the original article on People
Business Wire
14-05-2025
- Business
- Business Wire
IPS HEART Granted Orphan Drug Designation in the EU for Becker Muscular Dystrophy
HOUSTON--(BUSINESS WIRE)-- IPS HEART has been awarded Orphan Drug Designation (ODD) in the EU by the EUROPEAN MEDICINES AGENCY for GIVI-MPCs unique ability to create new muscle with 100% full length dystrophin in Becker Muscular Dystrophy (BMD). IPS HEART has now shown GIVI-MPCs can create new human muscle with full length human dystrophin in BMD dystrophic pigs, young and extremely aged Duchenne Muscular Dystrophy (DMD) mice and in a sarcopenia mouse model. The FDA previously awarded GIVI-MPCs Orphan Drug Designation for both BMD & DMD, highlighting the unique platform potential of GIVI-MPCs to reverse both devastating diseases. All current DMD therapeutics initially approved by the FDA through novel biomarkers including exon skipping and gene therapy therapeutics cannot produce 100% full length dystrophin nor can they create any new muscle to replace dead dystrophic muscle. While we are grateful to the dozens of BMD patients who have emailed us directly for information on our upcoming clinical trials, to date we are initially focused on advancing GIVI-MPCs clinically in a Phase I/II DMD clinical trial until we can secure additional partners to help us advance clinically in BMD. IPS HEART is currently under formal CDA with certain large pharmaceutical companies for a possible partnership that will also allow us to advance GIVI-MPCs clinically in BMD as we have already successfully produced GIVI-MPCs via large scale suspension based bioreactor manufacturing which can supply the large patient population in the future. About IPS HEART/GIVI-MPCs GIVI-MPCs derived from pluripotent stem cells form new skeletal muscle with 100% full-length human dystrophin for DMD and BMD. IPS HEART has also developed ISX-9-CPCs, a human iPSC-derived cardiac therapy for treatment of Duchenne cardiomyopathy and heart failure that develops new heart muscle. About Becker & Duchenne Muscular Dystrophy BMD is a muscular disease and DMD is a fatal neuromuscular disease.
Yahoo
14-05-2025
- Business
- Yahoo
IPS HEART Granted Orphan Drug Designation in the EU for Becker Muscular Dystrophy
HOUSTON, May 14, 2025--(BUSINESS WIRE)--IPS HEART has been awarded Orphan Drug Designation (ODD) in the EU by the EUROPEAN MEDICINES AGENCY for GIVI-MPCs unique ability to create new muscle with 100% full length dystrophin in Becker Muscular Dystrophy (BMD). IPS HEART has now shown GIVI-MPCs can create new human muscle with full length human dystrophin in BMD dystrophic pigs, young and extremely aged Duchenne Muscular Dystrophy (DMD) mice and in a sarcopenia mouse model. The FDA previously awarded GIVI-MPCs Orphan Drug Designation for both BMD & DMD, highlighting the unique platform potential of GIVI-MPCs to reverse both devastating diseases. All current DMD therapeutics initially approved by the FDA through novel biomarkers including exon skipping and gene therapy therapeutics cannot produce 100% full length dystrophin nor can they create any new muscle to replace dead dystrophic muscle. While we are grateful to the dozens of BMD patients who have emailed us directly for information on our upcoming clinical trials, to date we are initially focused on advancing GIVI-MPCs clinically in a Phase I/II DMD clinical trial until we can secure additional partners to help us advance clinically in BMD. IPS HEART is currently under formal CDA with certain large pharmaceutical companies for a possible partnership that will also allow us to advance GIVI-MPCs clinically in BMD as we have already successfully produced GIVI-MPCs via large scale suspension based bioreactor manufacturing which can supply the large patient population in the future. About IPS HEART/GIVI-MPCs GIVI-MPCs derived from pluripotent stem cells form new skeletal muscle with 100% full-length human dystrophin for DMD and BMD. IPS HEART has also developed ISX-9-CPCs, a human iPSC-derived cardiac therapy for treatment of Duchenne cardiomyopathy and heart failure that develops new heart muscle. About Becker & Duchenne Muscular Dystrophy BMD is a muscular disease and DMD is a fatal neuromuscular disease. View source version on Contacts Email: info@ Website: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Why Oddity Tech Ltd. (ODD) Declined on Tuesday
We recently published an article titled . In this article, we are going to take a look at where Oddity Tech Ltd. (NASDAQ:ODD) stands against the other stocks. Wall Street's main indices finished mixed on Tuesday, as investors digested the country's latest inflation figures, which came out lower than expected. On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, bringing the annual inflation rate to 2.3 percent, versus the 2.4 percent in March. It was the lowest annual rate since February 2021. Only the S&P 500 and the tech-heavy Nasdaq registered gains among all major indices, up by 0.72 percent and 1.61 percent, respectively. The Dow Jones, on the other hand, was down by 0.64 percent. Beyond the main indices, 10 firms lagged in performance amid negative news, sparking sell-offs. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A close-up of a customer's hands selecting beauty products from an online retailer. Oddity Tech Ltd. (NASDAQ:ODD) dropped for a second straight day on Tuesday, losing 14.16 percent to close at $60.16 apiece following its chief executive officer's disposal of a significant stake in the company. According to Oddity Tech Ltd. (NASDAQ:ODD), its CEO, Oran Holtzman, disposed of shares in the company to improve the trading liquidity of the stock. He added that he plans to maintain control in the firm, holding approximately 23 percent of ownership. He added that he entered into a one-year lock-up agreement, indicating that he had no intentions of selling additional shares. The sell-off was executed under Rule 144 of the Securities Act of 1933. Oddity Tech Ltd. (NASDAQ:ODD) is a consumer technology company that builds and scales digital-first brands to disrupt the offline-dominated beauty and wellness industries. Overall ODD ranks 5th on our list of Tuesday's worst performers. While we acknowledge the potential of ODD as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ODD but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
